IC
ABUS icon

Ikarian Capital’s Arbutus Biopharma ABUS Stock Holding History

Ikarian Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-115,000
Closed -$383K – 211
2021
Q1 		$383K Hold
115,000
– – 0.01% 262
2020
Q4 		$408K Hold
115,000
– – 0.02% 197
2020
Q3 		$360K Buy
+115,000
New +$350K 0.03% 147

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Ikarian Capital's ABUS Position: Q2 2021 in Review

Ikarian Capital sold out of Arbutus Biopharma (ABUS) in Q2 2021, closing a stake of 115,000 shares — an estimated $383K sold.

Ikarian Capital first reported a position in ABUS in Q3 2020 and held it in 3 quarters. The position peaked at $408K in Q4 2020. 91 funds tracked by Wall St. Rank hold ABUS as of Q2 2021.

  • Ikarian Capital reported no remaining Arbutus Biopharma position as of Q2 2021 after selling out during the quarter.
  • Ikarian Capital sold 115,000 Arbutus Biopharma shares in Q2 2021, an estimated $383K.
  • Ikarian Capital first reported a position in Arbutus Biopharma in Q3 2020 and held it in 3 quarters.
  • Ikarian Capital's Arbutus Biopharma position peaked at $408K in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2021.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.